Figure 8.
Subgroup analysis of PFS in immunotherapy inhibitor (A), anti-angiogenic agent (B), EGFR mutation (C) and whether or not to combine chemotherapy (D).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.